Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Bacteriophage therapeutic - MB Pharma

Drug Profile

Bacteriophage therapeutic - MB Pharma

Alternative Names: DUOFAG

Latest Information Update: 26 Jan 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator MB Pharma
  • Class Antibacterials; Antifungals; Bacteriophages
  • Mechanism of Action Bacterial DNA modulators; Bacterial RNA modulators; Cell death inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Surgical wound infections

Most Recent Events

  • 01 Jan 2023 State Institute for Drug Control approves clinical trial application for bacteriophage therapeutic for the treatment of Surgical wound infections before January 2023 (MB Pharma, January 2023)
  • 30 Dec 2022 Phase-I/II clinical trials in Surgical wound infections (In adults, In the elderly) in Czech Republic (Topical) (EudraCT2022-002412-23)
  • 31 Aug 2022 MB Pharma files a clinical trial application with the State Institute for Drug Control in Czechia for the treatment of Surgical wound infections (MB Pharma, January 2023)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top